Prostate stent is an option for selected patients who are unsuitable for transurethral resection of the prostate

Transurethral resection of the prostate (TUR-P) is the gold standard for treatment of severe lower urinary tract symptoms (LUTS) or urine retention. Some patients are unfit for surgery due to much co-morbidity and need alternative treatment. Intraprostatic stents are one example of minimally invasive treatment for LUTS. We present our results for 27 consecutive intraprostatic stents. A retrospective chart review of all patients who had received an intraprostatic stent between January 2012 and December 2013 by the same surgeon at the Department of Urology, Roskilde Hospital, Denmark. A total of 27 consecutive intraprostatic stents placed in 25 patients were reported. In all, 14 stents were still functioning at the end of follow-up after a mean 432.5 days. Four patients had died of reasons unrelated to the stent with a functioning stent in situ after an average of 102 days. A total of nine stents (33%) were removed in seven patients after a mean 165 days due to migration in two cases, infection in two cases, incontinence in two cases and retention in three cases. Residual urine was significantly reduced after placement of the stents. 72% of the patients avoided surgery or an indwelling catheter. An intraprostatic stent can be an important option in highly selected patients with considerable co-morbidity who are unsuitable for TUR-P. not relevant. not relevant.